ANGLE plc’s Parsortix a “game-changer” for prostate cancer detection, says CEO

Andrew Newland, chief executive of specialist med-tech company ANGLE plc (LON:AGL), believes the company’s Parsortix liquid biopsy could be a “real game-changer” in the battle against prostate cancer.

Data from a Barts Cancer Institute study suggested that the Parsortix system can not only detect the disease, but can also identify how aggressive it is.

Although Newland believes Parsortix will need at least 18 months of further research, he says he’s well aware that “there’s a tremendous opportunity here commercially”.